ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction

Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2